Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
31 hedge funds and large institutions have $1.68M invested in Navidea Biopharmaceuticals Inc. in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
7% more funds holding
Funds holding: 29 → 31 (+2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
39% less capital invested
Capital invested by funds: $2.76M → $1.68M (-$1.08M)
75% less call options, than puts
Call options by funds: $96K | Put options by funds: $379K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$208K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$72.1K |
| 3 |
VF
Virtu Financial
New York
|
+$35.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23.1K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$17.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.1K |
| 2 |
Two Sigma Advisers
New York
|
-$50.2K |
| 3 |
Two Sigma Investments
New York
|
-$48.3K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$48K |
| 5 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$16.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KFS
26
Kelly Financial Services
Braintree,
Massachusetts
| $50 | – | – | – |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$61.1K | -43,445 | Closed |
|
|
28
HighTower Advisors
Chicago,
Illinois
| – | -$48K | -28,465 | Closed |
|
29
Morgan Stanley
New York
| – | -$3.52K | -2,499 | -89% |
|
|
JCM
30
Jacobi Capital Management
Pittston,
Pennsylvania
| – | -$2K | -1,000 | Closed |
|
31
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$211 | -150 | -97% |
|
32
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$334 | +237 | New |
|
NAVB Hedge Fund Activity: Q4 2021 in Review
31 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2021, worth a combined $1.68M — down 39% from $2.76M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NAVB positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Group One Trading, adding an estimated $208K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $61.1K sold.
- 31 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2021, up from 29 in Q3 2021.
- Funds reported $1.68M of Navidea Biopharmaceuticals Inc. stock for Q4 2021, down 39% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2021 and 3 closed out, a net change of +2 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2021 was Group One Trading, an estimated $208K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2021 was Susquehanna International Group, an estimated $61.1K sold.
Based on aggregated 13F filings for Q4 2021.